Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575789 | 0.84 | NR4A1 (0.65) | MEN1KMT2APOLBKDM4EMAPT | |
| SCHEMBL2860448 | 0.81 | EGFR (0.49) | MEN1KMT2APOLBKDM4EMAPT | |
| SCHEMBL32667421 | 0.81 | MEN1 (1.00) | MEN1KMT2APOLBKDM4EMAPT | |
| SCHEMBL15782810 | 0.78 | MEN1 (0.70) | MEN1KMT2APOLBKDM4EMAPT | |
| SCHEMBL2859379 | 0.78 | SLC5A1 (0.50) | MEN1KMT2APOLBKDM4EMAPT | |
| Cytosporone N SCHEMBL27547840 | 0.77 | NR4A1 (0.79) | MEN1KMT2AMAPTCYP3A4NR4A1 | |
| SCHEMBL2861715 | 0.77 | HSP90AB1 (0.51) | MEN1KMT2APOLBKDM4ECYP3A4 | |
| 2,4,6-Trihydroxyacetophenone SCHEMBL27884985 | 0.76 | CYP3A4 (0.86) | MEN1KMT2APOLBKDM4EMAPT | |
| SCHEMBL4387171 | 0.75 | HSD17B1 (0.44) | MEN1KMT2APOLBKDM4EMAPT | |
| SCHEMBL13283682 | 0.74 | HSP90AB1 (0.55) | MEN1KMT2APOLBKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642880-B1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-7767693-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-7538224-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070032532-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1642880-A1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032532-A1 | Hsp90 family protein inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | MEN1 4773/4885KMT2A 3681/4885POLB 4195/4885 |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | MEN1 4773/4885KMT2A 3681/4885POLB 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.